As AstraZeneca chases rivals, immuno-oncology gets complicated

LONDON (Reuters) - Three years after Pfizer's failed bid for AstraZeneca, the British drugmaker aims to prove in the coming weeks that its cancer immunotherapy can deliver on bold sales forecasts made during that takeover battle.